Treatment of Neutropenic Patients With Fever Who Are Suspected to Have a Gram Positive Infection (a Specific Kind of Bacteria) - Full Text View

Treatment of Neutropenic Patients With Fever Who Are Suspected to Have a Gram Positive Infection (a Specific Kind of Bacteria)

This study has been completed.

Sponsored by:	Pfizer
Information provided by:	Pfizer
ClinicalTrials.gov Identifier:	NCT00035425

Purpose

This study will treat patients who have fever and neutropenia (after cancer chemotherapy) that is possibly due to a specific bacteria (gram positive bacteria)

Condition	Intervention	Phase
Neutropenia Fever Gram-Positive Bacterial Infections Neoplasms	Drug: Antibiotic Drug: Vancomycin	Phase III

MedlinePlus related topics:

Antibiotics Bacterial Infections Cancer Fever

Drug Information available for:

Vancomycin Vancomycin hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment

Eligibility

Ages Eligible for Study:	13 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary.

Inclusion Criteria:

Patients must have neutropenia (ANC less than 500) with fever (oral temp 38.3 C).
Patients must have a cancer with recent chemotherapy and risks factors for gram positive infections.

Exclusion Criteria:

Patients with fever due to known causes.
Patients with HIV.
Patients with recent bone marrow transplant.
Patients with an infected indwelling catheter that cannot be removed.
Patients who have received more than one day of another antibiotic before entering the trial.
Patients with endocarditis, osteomyelitis, meningitis, CNS infections.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00035425

Show 21 Study Locations

Sponsors and Collaborators

Pfizer

More Information

Link to ClinicalStudyResults.org Posting This link exits the ClinicalTrials.gov site

Study ID Numbers:	M/1260/0079
First Received:	May 3, 2002
Last Updated:	February 17, 2006
ClinicalTrials.gov Identifier:	NCT00035425
Health Authority:	United States: Food and Drug Administration

Keywords provided by Pfizer:

Pharmacia

Study placed in the following topic categories:

Fever

Bacterial Infections

Neutropenia

Gram-Positive Bacterial Infections

Hematologic Diseases

Agranulocytosis

Vancomycin

Leukocyte Disorders

Leukopenia

Granulocytopenia

Additional relevant MeSH terms:

Anti-Infective Agents

Anti-Bacterial Agents

Communicable Diseases

Neoplasms

Therapeutic Uses

Infection

Pharmacologic Actions

ClinicalTrials.gov processed this record on November 20, 2008